ArticleFrontiers in nutrition2025
A novel antioxidant peptide from black soybean [
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Ultrasound-Assisted Ternary Deep Eutectic Solvent Extraction of Total Flavonoids fromAntioxidants (Basel, Switzerland) · 2026Article
- Identification and Functional Characterization of Cytoprotective Crocodile-Derived Peptides against Oxidatively Stressed Human Keratinocytes.ACS omega · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oxidative stress-related diseases drive the demand for natural antioxidants, with plant-derived peptides emerging as promising candidates. This study focused on identifying and characterizing a novel antioxidant peptide from black soybean (Glycine max) aqueous extracts, targeting myeloperoxidase (MPO), a key enzyme in oxidative damage. Peptide components were profiled by liquid chromatography-tandem mass spectrometry (LC-MS/MS). The candidate peptide VPNHFNAP was selected via molecular docking and dynamics simulations against MPO, followed by binding affinity validation using surface plasmon resonance (SPR). Antioxidant capacity was assessed through DPPH/ABTS radical scavenging assays (IC50: 12.3 ± 0.8 μM and 9.7 ± 0.5 μM, respectively). Cytoprotective effects were evaluated in HaCaT cells under H
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.